PTPRC and leukemia: Although leukemia progression was effectively reduced in all treatment conditions when assessed by blood count of human CD45+ (hCD45+) cells, the combination arm did not have significantly less leukemic cells in the blood after 14 days of treatment (Fig. 3b).